Celcuity’s gedatolisib doubled progression-free survival (11.1 vs 5.6 months) compared with Novartis’ Piqray in a Phase 3 breast cancer trial presented at ASCO 2026, but fell short of high market expectations.
Cantor is bullish on Sensei Biotherapeutics for its cancer drug PIKTOR, with Phase 2 data soon as a key stock catalyst.
Celcuity’s drug showed strong results in breast cancer, boosting survival and raising hopes it could become a new standard treatment.
Celcuity shares jump 45% after Phase 3 trial shows gedatolisib significantly improves survival in HR+/HER2- breast cancer patients. Analysts raise price target to $95.
Financial firm Guggenheim gave Celcuity a Buy rating, predicting massive sales for its breast cancer drug, Gedatolisib.
Phase 3 VIKTORIA-1 trial shows gedatolisib triplet slashed disease progression risk by 76% in HR+/HER2- advanced breast cancer, with favorable safety.
